Baclofen reestablishes μ-opioid receptor levels modified by morphine withdrawal syndrome in either sex

Synapse

Volumn 54, Issue 1, 2004, Pages 24-29

  Diaz, Silvina L ^b   Kemmling, Alma K ^b   Bonavita, Carla D ^b   Rubio, Modesto C ^b   Balerio, Graciela N ^a  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b NONE

Author keywords

3H DAMGO ; Binding; GABA B; Mice; Naloxone precipitated withdrawal; Sex differences

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; DOPAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; SODIUM CHLORIDE; TRITIUM; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; EVALUATION; FEMALE; FRONTAL CORTEX; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PARAMETER; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SEX DIFFERENCE; WITHDRAWAL SYNDROME; ANIMAL; BRAIN; METABOLISM;

ANIMALS; BACLOFEN; BRAIN; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; FEMALE; GABA AGONISTS; MALE; MICE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; RECEPTORS, OPIOID, MU; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 4344561373     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20061     Document Type: Article

References (38)

1. Balerio GN, Rubio MC. 2002. Baclofen analgesia: involvement of the GABAergic system. Pharmacol Res 46:281-286.
2. Bassareo V, Tanda G, Di Chiara G. 1995. Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate-abstinence. Psychopharmacology (Berl) 122:202-205.
3. Belozertseva IV, Andreev BV. 2000. The effect of GABA-positive agents on the formation of morphine dependence and on the manifestations of a withdrawal syndrome. Eksp Klin Farmakol 63:19-23.
4. Bexis S, Ong J, White J. 2001. Attenuation of morphine withdrawal signs by the GABA(B) receptor agonist baclofen. Life Sci 70:395-401.
5. Bhargava HN, Gulati A. 1990. Down-regulation of brain and spinal cord μ-opiate receptors in morphine tolerant-dependent rats. Eur J Pharmacol 190:305-311.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Calvino B, Lagowska J, Ben-Ari Y. 1979. Morphine withdrawal syndrome: differential participation of structures located within the amygdaloid complex and striatum of the rat. Brain Res 177:19-34.
8. Candido J, Lufty K, Billings B, Sierra V Duttaroy A, Inturrisi CE, Yoburn BC. 1992. Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation. Pharmacol Biochem Behav 42:685-692.
9. B receptors are involved in the control of acute opiate withdrawal in isolated tissue. Prog Neuropsychopharmacol Biol Psychiatry 23:289-299.
10. Cicero TJ, Nock B, Meyer ER. 1996. Gender-related differences in the antinociceptive properties of morphine. J Pharmacol Exp Ther 279:767-773.
11. Cicero TJ, Nock B, Meyer ER. 1997. Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentration. J Pharmacol Exp Ther 282:939-944.
12. Cicero TJ, Ennis T, Ogden J, Meyer ER. 2000. Gender differences in the reinforcing properties of morphine. Pharmacol Biochem Behav 65:91-96.
13. Cicero TJ, Aylward SC, Meyer ER. 2003. Gender differences in the intravenous self-administration of mu opiate agonists. Pharmacol Biochem Behav 74:541-549.
14. Craft RM, Stratmann JA, Bartok RE, Walpole TI, King SJ. 1999. Sex differences in development of morphine tolerance and dependence in rat. Psychopharmacology 143:1-7.
15. Diaz SL, Kemmling AK, Balerio GN. 2000. Gender neurochemical alterations in mice morphine withdrawal syndrome. Prevention with baclofen. Biocell 24 poster 51:47.
16. Diaz SL, Kemmling AK, Rubio MC, Balerio GN. 2001. Lack of sex-differences in the prevention by baclofen of the morphine withdrawal syndrome in mice. Behav Pharmacol 12:75-79.
17. Diaz SL, Kemmling AK, Balerio GN. 2003. Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal. Neurochem Int 42:293-298.
18. El-Kadi AO, Sharif SI. 1995. Modification by muscimol of naloxone-precipitated withdrawal symptoms in morphine-dependent mice. Gen Pharmacol 26:1579-1581.
19. Espejo EF, Serrano MI, Caille S, Stinus L. 2001. Behavioral expression of opiate withdrawal is altered after prefrontocortical dopamine depletion in rats: monoaminergic correlates. Neuropsychopharmacology 25:204-212.
20. Hammer RP. 1985. The sex hormone-dependent development of opiate receptors in the rat medial preoptic area. Brain Res 360:65-74.
21. Hammer RP. 1990. Mu-opiate receptor binding in the medial preoptic area is cyclical and sexually dimorphic. Brain Res 515:187-192.
22. Kemmling AK, Rubio MC, Balerio GN. 2002. Baclofen prevents morphine withdrawal irrespective of seasonal variation. Behav Pharmacol 13:87-92.
23. Kepler KL, Standifer KM, Paul D, Kest B, Pasternak GW, Bodnar RJ. 1991. Gender effects and central opioid analgesia. Pain 45:87-94.
24. Koob GF, Stinus L, Le Moine C. 2000. Mapping of c-fos gene expression in the brain during morphine dependence and precipitated withdrawal, and phenotypic identification of the striatal neurons involved. Eur J Neurosci 12:4475-4486.
25. Lufty K, Yoburn BC. 1991. The role of opioid receptor density in morphine tolerance. J Pharmacol Exp Ther 256:575-580.
26. Nestler EJ, Aghajanian GK. 1997. Molecular and cellular basis of addiction. Science 278:58-63.
27. Oishi R, Ozaki M, Takemori AE. 1983. In vivo binding of naloxone to opioid receptors in morphine-dependent mice. Neuropharmacology 22:1015-1019.
28. Petruzzi R, Ferraro TN, Kurschner VC, Golden GT, Berrettini WH. 1997. The effects of repeated morphine exposure on mu opioid receptor number and affinity in C57BL/6J and DBA/2 mice. Life Sci 61:2057-2064.
29. 3N] Naltrexone to discrete brain regions and spinal cord of the rat. Gen Pharmacol 25:355-361.
30. Sivam SP, Nabeshima T, Ho IK. 1982. Alterations of synaptic high and low affinity opiate binding sites after acute and chronic morphine administration in mice. Prog Neuropsychopharmacol Biol Psychiatry 6:119-127.
31. Stafford K, Gomes AB, Shen J, Yoburn BC. 2001. Mu-opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav 69:233-237.
32. Tremblay EC, Charton G. 1981. Anatomical correlates of morphine-withdrawal syndrome: differential participation of structures located within the limbic system and striatum. Neurosci Lett 23:137-142.
33. Turchan J, Przewlocka B, Toth G, Lason W, Borsodi A, Przewlocki R. 1999. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience 91:971-977.
34. Yoburn BC, Nunes FA, Adler B, Pasternak GW, Inturrisi CE. 1986. Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse. J Pharmacol Exp Ther 239:132-135.
35. Yoburn BC, Sierra V, Lufty K. 1989. Chronic opioid antagonist treatment: assessment of receptor regulation. Eur J Pharmacol 170:193-200.
36. Yoshimura K, Yamamoto K. 1979. Neuropharmacological studies on drug dependence (I). Effects due to the difference in strain, sex and drug administration time on physical dependence development and characteristics of withdrawal signs in CNS-affecting drug dependent rats. Nippon Yakurigaku Zasshi 75:805-828.
37. Zarrindast MR, Mousa-Ahmadi E. 1999. Effects of GABAergic system on naloxone-induced jumping in morphine-dependent mice. Eur J Pharmacol 381:129-133.
38. Zubieta JK, Dannals RF, Frost JJ. 1999. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry 156:842-848.